MTOR Signaling in Lymphangioleiomyomatosis

Overview

Journal Lymphat Res Biol

Specialty Allergy & Immunology

Date 2010 Mar 19

PMID 20235885

Citations 10

Authors

Arnold S Kristof

Affiliations

Soon will be listed here.

Abstract

The protein mammalian target of rapamycin (mTOR) plays a central role in cell growth and proliferation. Excessive mTOR activity is a prominent feature of many neoplasms and hamartoma syndromes, including lymphangioleiomyomatosis (LAM), a destructive lung disease that causes progressive respiratory failure in women. Although pharmacological inhibitors of mTOR should directly target the pathogenesis of these disorders, their clinical efficacy has been suboptimal. Recent scientific findings reviewed here have greatly improved our understanding of mTOR signaling mechanisms, provided new insights into the control of cell growth and proliferation, and facilitated the development of new therapeutic approaches in LAM, as well as other neoplastic disorders that exhibit excessive mTOR activity.

Citing Articles

Lymphangioleiomyomatosis and pregnancy: a mini-review.

Zhou J, Diao M Arch Gynecol Obstet. 2024; 309(6):2339-2346.

PMID: 38594407 PMC: 11147845. DOI: 10.1007/s00404-024-07478-2.

Prdx5 in the Regulation of Tuberous Sclerosis Complex Mutation-Induced Signaling Mechanisms.

Bovari-Biri J, Abdelwahab E, Garai K, Pongracz J Cells. 2023; 12(13).

PMID: 37443747 PMC: 10340296. DOI: 10.3390/cells12131713.

Cystic Lung Disease Presenting as Recurrent Non-traumatic Chylothorax: Case Report and a Mini-Review.

Gupta S, Paul V Cureus. 2023; 15(6):e40217.

PMID: 37435256 PMC: 10332385. DOI: 10.7759/cureus.40217.

Tuberous sclerosis complex associated lymphangioleiomyomatosis.

Han Z, Xue X, Wang J, Lu D QJM. 2023; 116(10):873-874.

PMID: 37286375 PMC: 10593382. DOI: 10.1093/qjmed/hcad125.

Raising the Flag for Mast Cells as a Novel Target in Lymphangioleiomyomatosis.

Goldklang M Am J Respir Crit Care Med. 2021; 204(4):387-389.

PMID: 33951405 PMC: 8480237. DOI: 10.1164/rccm.202104-0872ED.

References

Murata K, Wu J, Brautigan D . B cell receptor-associated protein alpha4 displays rapamycin-sensitive binding directly to the catalytic subunit of protein phosphatase 2A. Proc Natl Acad Sci U S A. 1997; 94(20):10624-9. PMC: 23426. DOI: 10.1073/pnas.94.20.10624. View

Inui S, Sanjo H, Maeda K, Yamamoto H, Miyamoto E, Sakaguchi N . Ig receptor binding protein 1 (alpha4) is associated with a rapamycin-sensitive signal transduction in lymphocytes through direct binding to the catalytic subunit of protein phosphatase 2A. Blood. 1998; 92(2):539-46. View

NANAHOSHI M, Nishiuma T, Tsujishita Y, Hara K, Inui S, Sakaguchi N . Regulation of protein phosphatase 2A catalytic activity by alpha4 protein and its yeast homolog Tap42. Biochem Biophys Res Commun. 1998; 251(2):520-6. DOI: 10.1006/bbrc.1998.9493. View

Peterson R, Desai B, Hardwick J, Schreiber S . Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc Natl Acad Sci U S A. 1999; 96(8):4438-42. PMC: 16350. DOI: 10.1073/pnas.96.8.4438. View

Brugarolas J, Lei K, Hurley R, Manning B, Reiling J, Hafen E . Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004; 18(23):2893-904. PMC: 534650. DOI: 10.1101/gad.1256804. View

Goncharova E, Goncharov D, Noonan D, Krymskaya V . TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase. J Cell Biol. 2004; 167(6):1171-82. PMC: 2172598. DOI: 10.1083/jcb.200405130. View

Inoki K, Corradetti M, Guan K . Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2004; 37(1):19-24. DOI: 10.1038/ng1494. View

Sarbassov D, Guertin D, Ali S, Sabatini D . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-101. DOI: 10.1126/science.1106148. View

Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi P . Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005; 121(2):179-93. DOI: 10.1016/j.cell.2005.02.031. View

10.

Long X, Lin Y, Ortiz-Vega S, Yonezawa K, Avruch J . Rheb binds and regulates the mTOR kinase. Curr Biol. 2005; 15(8):702-13. DOI: 10.1016/j.cub.2005.02.053. View

11.

Platanias L . Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005; 5(5):375-86. DOI: 10.1038/nri1604. View

12.

Dames S, Mulet J, Rathgeb-Szabo K, Hall M, Grzesiek S . The solution structure of the FATC domain of the protein kinase target of rapamycin suggests a role for redox-dependent structural and cellular stability. J Biol Chem. 2005; 280(21):20558-64. DOI: 10.1074/jbc.M501116200. View

13.

Mak B, Kenerson H, Aicher L, Barnes E, Yeung R . Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol. 2005; 167(1):107-16. PMC: 1603434. DOI: 10.1016/s0002-9440(10)62958-6. View

14.

Manning B, Logsdon M, Lipovsky A, Abbott D, Kwiatkowski D, Cantley L . Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev. 2005; 19(15):1773-8. PMC: 1182339. DOI: 10.1101/gad.1314605. View

15.

Kristof A, Pacheco-Rodriguez G, Schremmer B, Moss J . LY303511 (2-piperazinyl-8-phenyl-4H-1-benzopyran-4-one) acts via phosphatidylinositol 3-kinase-independent pathways to inhibit cell proliferation via mammalian target of rapamycin (mTOR)- and non-mTOR-dependent mechanisms. J Pharmacol Exp Ther. 2005; 314(3):1134-43. DOI: 10.1124/jpet.105.083550. View

16.

Sarbassov D, Sabatini D . Redox regulation of the nutrient-sensitive raptor-mTOR pathway and complex. J Biol Chem. 2005; 280(47):39505-9. DOI: 10.1074/jbc.M506096200. View

17.

Roux P, Shahbazian D, Vu H, Holz M, Cohen M, Taunton J . RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem. 2007; 282(19):14056-64. PMC: 3618456. DOI: 10.1074/jbc.M700906200. View

18.

Land S, Tee A . Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem. 2007; 282(28):20534-43. DOI: 10.1074/jbc.M611782200. View

19.

Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S . The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem. 2007; 282(28):20329-39. PMC: 3199301. DOI: 10.1074/jbc.M702636200. View

20.

Pearce L, Huang X, Boudeau J, Pawlowski R, Wullschleger S, Deak M . Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J. 2007; 405(3):513-22. PMC: 2267312. DOI: 10.1042/BJ20070540. View